Clinical trials: Neoantigen
Esophageal Cancer, Neoantigen
Computational Prediction and Experimental Validation of Esophageal Cancer Associated Neoantigens
This study is to develop computational pipelines and experimental validation assays for improving the identification of neoantigens from patients with esophageal cancer.
- Trial name
- NCT05498168
- Testing
- ratio of predicted neoantigens
- Where
- Vietnam
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
High Risk Cancer, Pancreatic Cancer
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant for patients who have been identified to be at risk of developing pancreatic cancer.
- Trial name
- NCT05013216
- Testing
- Cohort A: Patients at high risk of developing pancreatic cancer., Cohort B: Patients must have evidence of a pancreatic cystic neoplasm
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer
Safety and Immune Response to FMPV-1
This is a single centre, open-label, non-randomized, Phase I study assessing safety and immune response of FMPV-1 in healthy male subjects.
- Trial name
- NCT05238558
- Testing
- FMPV-1, GM-CSF (as adjuvant)
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hubro Therapeutics AS
Diffuse Intrinsic Pontine Glioma
Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma
Diffuse intrinsic pontine gliomas (DIPGs), which diffusely occupy the pons of brainstem, are the deadliest primary brain cancer in children.
- Trial name
- ENACTING (NCT04749641)
- Testing
- Histone H3.3-K27M Neoantigen Vaccine Therapy
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Yang Zhang